ViRexx Medical Corp. (TSX:VIR) a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, today announced interim results from its Phase I clinical trail that is evaluating the Company’s proprietary OcclusinTM 50 Injection embolotherapy to treat liver cancer as part of a transcatheter arterial chemoembolization (TACE) procedure. Treatment and monitoring of five of a targeted twelve liver cancer patients has been completed. The interim results demonstrated stable disease for each of the five patients. There have been no product related severe adverse events.
